Ambrisentan (Letairis®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS AMBRISENTAN?

First Page		Document Content
Date: 2013-12-03 14:16:08 Pyrimidines Sulfonamides Ambrisentan Ethers Bosentan Endothelin receptor antagonist Pulmonary hypertension Endothelin Methadone Chemistry Organic chemistry Orphan drugs		Ambrisentan (Letairis®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS AMBRISENTAN? Add to Reading List Source URL: www.phassociation.org Download Document from Source Website File Size: 226,45 KB Share Document on Facebook

	Clinical Commissioning Policy: Clinical Commissioning Policy: National policy for targeted DocID: 18zFu - View Document
	Kwartaalbericht 4e kwartaalNovember 2005 Contents DocID: 15SVk - View Document
	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. DocID: 15iVb - View Document
	Better understanding of blood vessel constrictor needed to harness its power for patients DocID: RsPy - View Document
	Bosentan (Tracleer®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS BOSENTAN? DocID: QGSp - View Document